Xeris Biopharma Holdings, Inc. XERS Concentration Risk %

Other financials

Revenue$83.1M+38.3%

Gross profit$72.6M+41.2%

Operating income$7.9M+356%

Net income$2.2M+124%

EPS (diluted)$0.01+117%

Cash & equivalents$111.8M+91.2%

Total debt$258.6M-3.8%

Total equity$13.0M+137%

Total assets$392.0M+24.3%

Operating cash flow$9.9M+198%

CapEx$131.0K—

Free cash flow-$29.1M—

Market cap$1.28B+76.9%

Enterprise value$1.42B+52.7%

P/E106.4×—

P/S4.1×+0.8×

Gross margin85.9%+3.7pp

Operating margin11.4%+7.7pp

Net margin3.8%+2.1pp

Return on equity-209.8%—

Debt / equity19.9×—

Current ratio2.1×+0.4×